非霍奇金淋巴瘤患者PET/CT标准摄取值与血清乳酸脱氢酶、β2微球蛋白及Ki-67阳性率的相关性

黄海彬; 罗晓丹; 陈保荣; 覃鹏飞; 郑润辉; 刘丹; 王春燕; 黄振倩; 谭获

非霍奇金淋巴瘤患者PET/CT标准摄取值与血清乳酸脱氢酶、β2微球蛋白及Ki-67阳性率的相关性

- 广州医学院第一附属医院血液肿瘤中心(广州, 510230)

详细信息

通讯作者: 谭获,E-mail:tanhuo.2008@163.com

中图分类号: R733.4

收稿日期: 2013-01-10

Correlation of PET/CT standardized uptake value and lactic dehydrogenase, β2-microglobulin and Ki-67 positive rate in non-Hodgkin's lymphoma

- Center of Hematology & Oncology, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou, 510230, China

More Information

Corresponding author: TAN Huo, E-mail: tanhuo.2008@163.com

Received Date: 10 January 2013

摘要

摘要: 目的：探讨非霍奇金淋巴瘤（NHL）患者PET/CT标准摄取值（SUV）与血清乳酸脱氢酶（LDH）、血清β2微球蛋白（S-β2M）及Ki-67阳性率的相关性。方法：统计分析50例初诊NHL患者SUV与LDH、S-β2M、Ki-67阳性率表达之间的相关性。结果：SUV与LDH（r=0.400，P<0.05）和S-β2M（r=0.406，P<0.01）均呈正相关。追踪分析其中23例患者治疗后的变化发现，SUV、LDH和S-β2M均明显下降（均P<0.01）。SUV与Ki-67阳性率也有相关性（P=0.000）。受试者工作曲线结果提示，SUV、LDH和S-β2M能较准确反映NHL的侵袭性，曲线下面积分别为0.800、0.780和0.785。结论：SUV、LDH和S-β2M均可作为NHL恶性程度及评价疗效的参考指标。
- 非霍奇金淋巴瘤 /
- 正电子发射断层现象 /
- 标准摄取值 /
- 乳酸脱氢酶 /
- β2微球蛋白
Abstract: Objective: To explore the correlation of PET/CT standardized uptake value (SUV) and serum lactic dehydrogenase (LDH),β2-microglobulin (S-β2M) and Ki-67 positive rate in non-Hodgkin's lymphoma (NHL) patients.Method: We analyzed the relationship between SUV and LDH,S-β2M,Ki-67 in 50 cases diagnosed with NHL in the first time.Result: SUV was positively correlated with LDH (r=0.400,P<0.05) and S-β2M (r=0.406,P<0.01).Tracking analysis of the changes after treatment of 23 patients showed that SUV,LDH and S-β2M were significantly decreased (all P<0.01).SUV and Ki-67 positive rate was also relevant (P=0.000).SUV,LDH and S-β2M could accurately reflect the invasiveness of the NHL,and the area under the curve was 0.800,0.780 and 0.785.Conclusion: SUV,LDH and S-β2M can be used as the reference indicators for evaluating the degree of malignancy and the efficacy of treatment in NHL.
- non-Hodghin's lymphoma /
- PET/CT /
- standardized uptake value /
- lactic dehydrogenase /
- β2-microglobulin

HTML全文

参考文献(9)

[1]	ZELENTZ A D,ABRAMSON J S,ADVANI R H,et al.NCCN Clinical Practice Guidelines in Oncology:non-Hodgkin's lymphomas[J].J Natl Compr Canc Netw,2010,8:288-334.
[2]	CHESON B D.Role of functional imaging in the management of lymphoma[J].J Clin Oncol,2011,29:1844-1854.
[3]	BRAGG D G,OKUNO W,HRICAK H.Hodkin's disease,lymphomas and the lymphoproliferative disorders[M]//Bragg D G,Rubin P,Hricak H.Oncologic Imaging.2nd ed.Philadelphia:WS Saunders,2002:855-883.
[4]	JUWEID M E,CHESON B D.Role of positron emission tomography in lymphoma[J].J Clin Oncol,2005,23:4577-4580.
[5]	吕方芳,陆洪芬,印季良,等.Survivin、bcl-2及Ki-67在弥漫大B细胞淋巴瘤中的表达及临床意义[J].肿瘤,2006,26(10):930-934.
[6]	刘勇,路名芝,张文书.弥漫性大B细胞淋巴瘤不同免疫类型中bcl-2、Ki-67的表达及相互关系[J].临床与实验病理学杂志,2007,23(3):369-370.
[7]	尚晋,陈志忠,魏天男,等.Ki-67对弥漫大B细胞淋巴瘤预后评估的意义[J].临床血液学杂志,2012,25(4):445-448.
[8]	YANG L,XU X H,PENG C L,et al.Prognostic values of serum LDH and β2-MG in patients with non-Hodgkin's lymphoma[J].Chin-German J Chin Oncol,2009,8:353-355.
[9]	江红,李佩章,劳明.血清LDH和β2-MG水平与非霍奇金淋巴瘤的预后关系[J].医学研究杂志,2008,37(10):91-92.